SEATTLE, Feb. 13, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it will deliver an invited presentation on February 15th, 2018 at 4:15 PM as part of the Adoptive T- Cell Therapy Symposium at the Hilton San Francisco Union Square in San Francisco, CA. The symposium will be held during the 25th Annual Molecular Medicine Tri-Conference, one of the world’s premier international events in the field of drug discovery, development and diagnostics.
The presentation entitled “TRAP CAR-T and Related Cell Therapies: Can Local Delivery Solve Efficacy and Toxicity Challenges in Solid Tumor Immuno-Oncology?” will discuss Atossa’s proprietary intraductal microcatheter technology and its potential to deliver T-Cell and other immunotherapies directly to breast cancer tumors.
Janet Rea, MSPH, RAC, Senior Vice President of Regulatory, Quality and Clinical Affairs for Atossa will present. Ms. Rea joined Atossa in 2015 and has over 35 years of industry leadership experience. A Washington native, she obtained her B.S. degree in Microbiology from the University of Washington and was conferred a Master’s of Science of Public Health from the same institution.
About The Molecular Medicine Tri-Conference
The annual Molecular Medicine Tri-Conference has become one of the world’s leading international events in the field of drug discovery, development and diagnostics. The Tri-Conference unites an ecosystem of 3,700 innovative thinkers and thought leaders throughout biotech, pharma and academia from around the world. Spanning five days (February 11 – 16) the 2018 meeting includes 16 parallel conference tracks, 7 Symposia, and 25 in-depth short courses.
About Atossa’s CAR-T Technology
Much of the recent success in the field of chimeric antigen receptor therapy, or CAR-T, has relied on the systemic delivery (for example a needle injection into the blood stream) of the CAR-T which is intended to treat various non-solid tumor cancers, such as blood cancers. One concern with this systemic approach is that it does not target the location of the cancer and it can have adverse affects, including deadly “cytokine storms.” Moreover, CAR-T treatments delivered systemically can be very expensive – as high as $500,000 per patient.
We are developing a novel method to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. This approach uses our proprietary intraductal microcatheter technology for the potential transpapillary, or “TRAP,” delivery of either T-cells that have been genetically modified to attack breast cancer cells or various immune-therapies. We believe this method has several potential advantages including the reduction of toxicity by limiting systemic exposure of the T-cells or immunotherapy; improved efficacy by placing the T-cells or immunotherapy in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and, lymphatic migration of the CAR-T cells or immunotherapy potentially extending their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination. Moreover, our proprietary approach may be more cost effective if lower doses of therapy can be delivered compared to systemic CAR-T. Our approach is in the R&D stage and is currently not FDA approved. In 2018 we intend to commence studies that will help demonstrate safety and efficacy of this novel approach.
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, preliminary and final results of clinical studies, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
CFO and General Counsel
Investor Relations Contact:
377 Oak Street
Garden City, NY 11530